Das Bild zeigt rechts ein Trichterglas mit blauer Flüssigkeit und Glasstab zum Umrühren. Daneben steht ein Reagenzglasständer mit Reagenzgläsern, die ebenfalls blaue Flüssigkeit enthalten. Im Hintergrund ist ein Forscher zu sehen, der in der rechten Hand eine Pipette hält.

Publikationen

Sie befinden sich hier:

2017

Bonnekoh H, Ohanyan T, Lenze D, Krause K, Maurer M, Zuberbier T, Siebenhaar F. Development of tripe Palms and soles in a Patient with Long pre-existing systemic mastocytosis and newly developed non-small cell lung cancer. J Eur Acad Dermatol Venereol. 2017 Oct 21. doi: 10.1111/jdv.14648. PubMed

Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel, M, Vollbrecht, C, Penzel R, Volckmar AL, Stenzinger A, Endris V, Jung A, Lehmann U, Zeugner S, Baretton G, Kreipe H, Schirmacher P, Kirchner T, Dietel M, Büttner R, Merkelbach-Bruse S. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin Trial. Virchows Arch. 2017 Sep 8. doi: 10.1007/s00428-017-2226-8. PubMed

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A. Mutational frequencies of CD79B and MYD88 vary greatly between Primary testicular DLBCL and gastrointestinal DLBCL. Leuk Lymphoma. 2017 Sep 3:1-4. doi: 10.1080/10428194.2017.1370546. PubMed

Zamò A, Pischimarov J, Schlesner M, Rosenstiel P, Bomben R, Horn H, Grieb T, Nedeva T, López C, Haake A, Richter J, Trümper L, Lawerenz C, Klapper W, Möller P, Hummel M, Lenze D, Szczepanowski M, Flossbach L, Schreder M, Gattei V, Ott G, Sibert R, Rosenwald A, Leich E. Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.270. PubMed

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G; German High-Grade Lymphomas Study Group. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. PubMed

Büttner J, Lehmann A, Klauschen F, Hummel M, Lenze D, Dietel M, Jöhrens K. Influence of mucinous and necrotic tissue in colorectal cancer samples on KRAS mutation analysis. Pathol Res Pract. 2017 Jun;213(6):606-611. doi: 10.1016/j.prp.2017.04.028. PubMed

Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH. Folic acid phenotype (FAP) is a superior biomarker predicting Response to pemetrexed-based chemotherapy in malignant pleural mesothelioma. Oncotarget. 2017 Jun 6;8(23):37502-37510. doi: 10.18632/oncotarget.16398. PubMed

Schwarzfischer P, Reinders J, Dettmer K, Kleo K, Dimitrova L, Hummel M, Feist M, Kube D, Szczepanowski M, Klapper W, Taruttis F, Engelmann JC, Spang R, Gronwald W, Oefner PJ. Comprehensive Metaboproteomics of Burkitt's and Diffuse Large B-Cell Lymphoma Cell Lines and Promary Tumor Tissues Reveals Distinct Differences in Pyruvate Content and Metabolism. J Proteome Res. 2017 Mar 3;16(3):1105-1120. doi: 10.1021/acs.jproteome.6b00164. PubMed

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliviera C, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C. DNA copy number changes define spatial Patterns of heterogeneity in colorectal cancer. Nat Commun. 2017 Jan 25;8:14093. doi: 10.1038/ncomms14093. PubMed

 

 

2016

Treese C, Sanchez P, Grabowski P, Berg E, Bläker H, Kruschewski M, Haase O, Hummel M, Daum S. Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas. PloS One. 2016 Dec 28;11(12):e0168237. doi: 10.1371/Journal.pone.0168237. PubMed

Otto C, Scholtysik R, Schmitz R, Kreuz M, Becher C, Hummel M, Rosenwald A, Trümper L, Klapper W, Siebert R, Küppers R; Molecular Mechanisms in Malignant Lymphomas Network Project. Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas. Genes Chromosomes Cancer. 2016 Dec;55(12):932-943. doi: 10.1002/gcc.22391. PubMed

Haider A, Steininger A, Ullmann R, Hummel M, Dimitrova L, Beyer M, Vandersee S, Lenze D, Sterry W, Assaf C, Möbs M. Inactiviation of RUNX3/p46 Promotes Cutaneous T-Cell Lymphoma. J Invest Dermatol. 2016 Nov;136(11):2287-2296. doi: 10.1016/j.jid.2016.05.126. PubMed

Grünewald I, Trautmann M, Busch A, Bauer L, Huss S, Schweinshaupt P, Vollbrecht C, Odenthal M, Quaas A, Büttner R, Meyer MF, Beutner D, Hüttenbrink KB, Wardelmann E, Stenner M, Hartmann W. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas. Oncotarget. 2016 Nov 15;7(46):75261-75272. doi: 10.18632/oncotarget.12127PubMed

Walter RF, Werner R, Vollbrecht C, Hager T, Flom E, Christoph DC, Schmeller J, Schmidt KW, Wohlschlaeger J, Mairinger FD. ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology. PloS One. 2016 Nov 1;11(11):e0165181. doi: 10.1371/Journal.pone.0165181PubMed

Hezaveh K, Kloetgen A, Bernhart SH, Mahapatra KD, Lenze D, Richter J, Haake A, Bergmann AK, Brors B, Burkhardt B, Claviez A, Drexler HG, Eils R, Haas S, Hoffmann S, Karsch D, Klapper W, Kleinheinz K, Kretzmer H, Kreuz M, Küppers R, Lawerenz, C, Leich E, Loeffler M, Mantovani-Loeffler L, López C, McHardy AC, Möller P, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schlesner M, Scholz I, Stadler PF, Stilgenbauer S, Sungalee S, Szczepanowski M, Trümper L, Weniger MA, Siebert R, Borkhardt A, Hummel M, Hoell JI; ICGC MMML-Seq Project. Alterations of microRNA and microRNA-regulated messenger RNA Expression in germinal Center B-cell lymphomas determined by integrative sequencing Analysis. Haematologica. 2016 Nov;101(11):1380-1389. PubMed

Walter RF, Vollbrecht C, Christoph D, Werner R, Schmeller J, Flom E, Trakada G, Rapti A, Adamidis V, Hohenforst-Schmidt W, Kollmeier J, Mairinger T, Wohlschlaeger J, Zarogoulidis P, Porpodis K, Schmidt KW, Mairinger FD. Massive parallel sequencing and digital gene Expression Analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors. J Cancer. 2016 Oct 25;7(15):2165-2172. PubMed

Joosten M, Ginzel S, Blex C, Schmidt D, Gombert M, Chen C, Linka RM, Gräbner O, Hain A, Hirsch B, Sommerfeld A, Seegebarth A, Gruber U, Maneck C, Zhang L, Stenin K, Dieks H, Sefkow M, Münk C, Baldus CD, Thiele R, Borkhardt A, Hummel M, Köster H, Fischer U, Dreger M, Seitz V. A novel Approach to detect resistance mechanisms reveals FGR as factor mediating HDAC Inhibitor SAHA resitance in B-cell lymphoma. Mol Oncol. 2016 Oct;10(8):1232-44. doi: 10.1016/j.molonc.2016.06.001PubMed

Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, Wohlschlaeger J, Barbetakis N, Paliouras D, Chatzinikolaou, Adamidis V, Tsakiridis K, Zarogoulidis P, Trakada G, Christoph DC, Schmid KW, Mairinger FD. Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. J Cancer. 2016 Sep 13;7(13):1915-1925. PubMed

Walter RF, Mairinger FD, Werner R, Vollbrecht C, Hager T, Schmid KW, Wohlschlaeger J, Christoph DC. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget. 2016 Apr 12;7(15):20166-79. doi: 10.18632/oncotarget.7737. PubMed

Walter RF, Vollbrecht C, Werner R, Wohlschlaeger J, Christoph DC, Schmid KW, Mairinger FD. microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. Oncotarget. 2016 Apr 5;7(14):18713-21. doi: 10.18632/oncotarget.7666. PubMed